PDF factsheet
      Z

antiplatelets drug in acute coronary syndrome for STEMI patients, clinical trials results

aspirin versus control
Huddinge, 1988
aspirin 500mg/d starting 12 h after admissionand and then intermittently every third day for one month
versus
no aspirin
patients with acute myocardial infarctionopen
Follow-up duration: 30d (12m)
Frankfurt, 1976
A1320 + D300, A1320
versus

Follow-up duration: 14d
aspirin versus placebo
ISIS-pilot, 1987
aspirin (325 mg on alternate days for 28 days)
versus
placebo
suspected acute myocardial infarctiondouble blind
Follow-up duration: 1m
ISIS-2, 1988
160 mg/day enteric-coated aspirin for one month
versus
placebo
suspected acute myocardial up to 24hdouble blind
Follow-up duration: 35d
Dutch-aspirin, 1990
aspirin (100 mg/day) for 3 months
versus
placebo
patients with first anterior wall AMIdouble blind
Follow-up duration: 3m
APRICOT, 1993
325 mg aspirin daily with discontinuation of heparin
versus
placebo
Patients treated with intravenous thrombolytic therapy followed by intravenous heparin and with patent infarct-related artery demonstrated at angiography within 48 hoursdouble blind
Follow-up duration: 3m
The Netherlands
clopidogrel versus placebo
COMMIT, 2005
NCT00222573
clopidogrel 75 mg daily
versus
placebo
patients admitted to hospital within 24 h of suspected acute MI onset double-blind
Follow-up duration: until discharge or up to 4 wee
CLARITY-TIMI 28, 2005
clopidogrel (300-mg loading dose, followed by 75 mg once daily)
versus
placebo
patients, 18 to 75 years of age, within 12 hours after the onset of an ST-elevation myocardial infarction double blind
Follow-up duration: 30 days
dazoxiben versus control
Jones, 1987
DZ
versus

Follow-up duration: 1m
elinogrel versus placebo
ERASE-MI, 2009
elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus
versus
placebo
STEMI patients double blind
Follow-up duration: 30-37 days
flurbiprofen versus placebo
French, 1993
flurbiprofen 50 mg twice daily
versus
placebo
patients successfully treated for acute MI by thrombolysis and/or coronary angioplasty within 6 h of onset of symptomsdouble blind
Follow-up duration: 6m
GR3219B versus control
GRAND, 1987
GRB
versus

Follow-up duration: 1m
misc. versus control
Gent-AMI, 1968
D400
versus

Follow-up duration: 28d
Johannessen, 1989
A150 + D225
versus

Follow-up duration: 14d
sulfinpyrazone versus control
Dutch sulphinpyrazone, 1986
S (W)
versus

Follow-up duration: 21d
sulfinpyrazone versus placebo
Wilcox, 1980
Sulphinpyrazone 200 mg four times daily
versus
placebo
patients with acute myocardial infarction
Follow-up duration: 10d
Louvain sulphinpyrazone, 1983
sulphinpyrazone, 4 x 200 mg daily for 7 days
versus
placebo
recent myocardial infarction double blind
Follow-up duration: 7d
ticlopidine versus control
Knudsen-A, 1985
ticlopidine 500mg/d
versus
placebo
patients with AMI double blind
Follow-up duration: 3m

  Options


in first

in second

  Filter